Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash & Equivalents (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Cash & Equivalents data on record, last reported at $333.3 million in Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 690.26% to $333.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $333.3 million, a 690.26% increase, with the full-year FY2025 number at $197.5 million, down 18.04% from a year prior.
  • Cash & Equivalents reached $333.3 million in Q1 2026 per FULC's latest filing, up from $197.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for FULC hit a ceiling of $333.3 million in Q1 2026 and a floor of $30.1 million in Q3 2023.
  • A 5-year average of $106.4 million and a median of $47.1 million in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 66.93% in 2022, then soared 690.26% in 2026.
  • Tracing FULC's Cash & Equivalents over 5 years: stood at $35.1 million in 2022, then soared by 573.03% to $236.2 million in 2023, then grew by 2.03% to $241.0 million in 2024, then dropped by 18.04% to $197.5 million in 2025, then soared by 68.74% to $333.3 million in 2026.
  • Business Quant data shows Cash & Equivalents for FULC at $333.3 million in Q1 2026, $197.5 million in Q4 2025, and $47.1 million in Q3 2025.